Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
TRACON Pharmaceuticals, Inc. TCON
$0.65
-$0.01 (-2.12%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
15696438.00000000
-
week52high
2.32
-
week52low
0.65
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.37197200
-
EPS
-1.35000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Baird | Outperform | 23 февр 2022 г. | |
| Alliance Global Partners | Buy | 04 июн 2021 г. | |
| BTIG | Buy | Neutral | 16 апр 2021 г. |
| Jones Trading | Buy | 01 апр 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 04 дек 2020 г. |
| JonesTrading | Buy | 01 апр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| THEUER CHARLES | A | 332000 | 332000 | 01 февр 2023 г. |
| Brown Scott B. | A | 144000 | 144000 | 01 февр 2023 г. |
| THEUER CHARLES | A | 339918 | 6800 | 18 янв 2023 г. |
| Brown Scott B. | A | 21628 | 3500 | 29 дек 2022 г. |
| LARUE WILLIAM R | D | 7763 | 120 | 21 дек 2022 г. |
| Opaleye Management Inc. | A | 440000 | 27500 | 14 дек 2022 г. |
| Opaleye Management Inc. | A | 4150000 | 140000 | 14 дек 2022 г. |
| THEUER CHARLES | A | 333118 | 23000 | 14 дек 2022 г. |
| Opaleye Management Inc. | D | 1667974 | 221539 | 06 дек 2022 г. |
| Opaleye Management Inc. | D | 4010000 | 1539 | 06 дек 2022 г. |
Новостная лента
TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript
Seeking Alpha
10 мая 2023 г. в 22:18
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Edward White - H.C. Wainwright & Co., LLC Joel Beatty - Robert W.
Why Is TRACON Pharma (TCON) Stock Down 51% Today?
InvestorPlace
25 апр 2023 г. в 09:11
TRACON Pharmaceuticals (NASDAQ: TCON ) stock is falling on Tuesday following an update on a legal battle with I-Mab (NASDAQ: IMAB ). The bad news for TCON stock comes from a legal ruling favoring I-Mab.
Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
14 мар 2023 г. в 13:44
Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript
Seeking Alpha
08 мар 2023 г. в 20:00
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Soumit Roy - Jones Research Joel Beatty - Robert W. Baird & Co. Robert Hazlett - BTIG Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call.
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
GlobeNewsWire
28 февр 2023 г. в 16:02
SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.